32 recruiting. 32 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 32 | Recruiting 32 |
| Phase 1 | 3 | Recruiting 3 |
| Phase 3 | 3 | Recruiting 3 |
Follow Dermatitis, Atopic: new trials by email Literature Review of Dermatitis, Atopic trials Research Report on Dermatitis, Atopic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis 0.5% AR100DP1, Placebo - Dermatitis Atopic | Phase 2 | Recruiting | Arjil Pharmaceuticals LLC | 40 | 2026-10-21 | 2026-11-03 |
| Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis LT-002-158, Placebo - Atopic Dermatitis (AD) | Phase 2 | Recruiting | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | 160 | 2026-10-01 | 2026-10-26 |
| PRA-216 Atopic Dermatitis Safety and Efficacy Study Active PRA-216, Placebo - Atopic Dermatitis (AD) | Phase 2 | Recruiting | Prana Therapies Inc | 39 | 2026-09-17 | 2026-10-28 |
| A Study Evaluating TRIV-573 in Atopic Dermatitis TRIV-573, Placebo - Atopic Dermatitis | Phase 2 | Recruiting | Triveni Bio | 90 | 2026-09-09 | 2026-10-28 |
| A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis ENV-294, Placebo - Atopic Dermatitis | Phase 2 | Recruiting | Enveda Therapeutics | 200 | 2026-06-29 | 2026-08-06 |
| A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis VC005 group, VC005 Placebo group - Atopic Dermatitis | Phase 2 | Recruiting | Jiangsu vcare pharmaceutical technology co., LTD | 120 | 2026-06-01 | 2026-07-07 |
| A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis Camoteskimab, Placebo - Atopic Dermatitis, Atopic | Phase 2 | Recruiting | Apollo Therapeutics Ltd | 280 | 2026-05-28 | 2026-08-28 |
| HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis HL-300, Placebo - Atopic Dermatitis | Phase 1 / Phase 2 | Recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 156 | 2026-05-26 | 2026-06-23 |
| A Clinical Study to Evaluate SM17 for Atopic Dermatitis SM17 for subcutaneous injection, SM17 placebo for subcutaneous injection - Atopic Dermatitis | Phase 2 | Recruiting | SinoMab BioScience Ltd | 200 | 2026-03-31 | 2026-04-06 |
| A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis IBI3002, Placebo, Dupilumab - Atopic Dermatitis | Phase 2 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 120 | 2026-02-06 | 2026-02-13 |
| A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis The high-dose group of ZL-82 tablets, The low-dose group of ZL-82 tablets, The placebo group - Atopic Dermatitis | Phase 2 | Recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 111 | 2026-02-03 | 2026-02-04 |
| Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD Soquelitinib, Placebo - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 2 | Recruiting | Corvus Pharmaceuticals, Inc. | 200 | 2026-02-01 | 2026-03-05 |
| Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome Abrocitinib - Atopic Dermatitis, Alopecia Areata | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 56 | 2026-01-12 | 2026-10-16 |
| Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis ENV-294, Placebo - Atopic Dermatitis (AD) | Phase 2 | Recruiting | Enveda Therapeutics | 105 | 2025-12-22 | 2026-09-25 |
| A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis. CM512 - Atopic Dermatitis (AD) | Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 246 | 2025-12-01 | 2025-11-17 |
| Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study Oral roflumilast - Atopic Dermatitis | Phase 2 | Recruiting | Nora Mohamed Abdelrazik | 36 | 2025-11-20 | 2025-12-30 |
| A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema PF-08049820, Placebo - Atopic Dermatitis, Eczema, Atopic | Phase 2 | Recruiting | Pfizer | 165 | 2025-11-20 | 2026-11-05 |
| A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) GX-03, Vehicle - Eczema Atopic Dermatitis, Eczema | Phase 2 / Phase 3 | Recruiting | Turn Therapeutics | 190 | 2025-07-11 | 2026-09-04 |
| Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis Placebo Comparator, CM512 - Atopic Dermatitis | Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 200 | 2025-06-19 | 2025-08-17 |
| A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis IMG-007, Placebo - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 2 | Recruiting | Inmagene LLC | 405 | 2025-06-17 | 2026-08-12 |
Showing 20 of 32. Sign in to see all of them.
Eczema (10) · Dermatitis (5) · Skin Diseases (4) · Skin Diseases, Genetic (2) · Alopecia Areata (1) · Down Syndrome (1) · Exanthema (1) · Food Hypersensitivity (1) · Hidradenitis Suppurativa (1) · Immune System Diseases (1) · Pruritus (1) · Skin Diseases, Eczematous (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (32) · Genetic Diseases, Inborn (32) · Hypersensitivity (32) · Hypersensitivity, Immediate (32) · Skin and Connective Tissue Diseases (32) · Immune System Diseases (31) · Skin Diseases, Eczematous (31) · Skin Diseases, Genetic (30) · Skin Diseases (28) · Dermatitis (27) · Abnormalities, Multiple (1) · Alopecia (1) · Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Chromosome Disorders (1)
Cephalexin (1) · Doxycycline (1) · Injections, Subcutaneous (1) · Roflumilast (1) · Sodium Hypochlorite (1) · Starch (1) · Sucrose (1) · Sulfamethoxazole (1) · Tablets (1) · Trimethoprim (1) · abrocitinib (1) · dupilumab (1) · lutikizumab (1)
Enveda Therapeutics (2) · Keymed Biosciences Co.Ltd (2) · Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · AbbVie (1) · Alphyn Biologics (1) · Apogee Therapeutics, Inc. (1) · Apollo Therapeutics Ltd (1) · Arjil Pharmaceuticals LLC (1) · Chengdu Zenitar Biomedical Technology Co., Ltd (1) · Chinese University of Hong Kong (1) · Corvus Pharmaceuticals, Inc. (1) · En Chu Kong Hospital (1) · Hangzhou Highlightll Pharmaceutical Co., Ltd (1) · Icahn School of Medicine at Mount Sinai (1)
United States (16) · China (12) · Canada (6) · Czechia (4) · Germany (4) · Poland (4) · Taiwan (4) · Australia (3) · France (3) · Hungary (3) · Spain (3) · Bulgaria (2) · Japan (2) · New Zealand (2) · United Kingdom (2)
Gurpreet Ahluwalia, PhD (2) · Jianzhong Zhang (2) · Abeer Mohamed Elkholy, MD Dermatology (1) · Chia-Yu Chu (1) · Dusan Bogunovic, PhD (1) · Emma Guttman, MD (1) · Gary Pekoe, PhD (1) · Heidi H Kong, M.D. (1) · Ian A Myles, M.D. (1) · Isin Sinem Bagci, MD (1) · Liming Wu (1) · Pamela A Frischmeyer-Guerrerio, M.D. (1) · Wu Liming NA, Doctor of Medicine (1)
2025 (1), R61AR084210 (1)